Phase II trial of 4'-epi-doxorubicin in patients with non-small cell lung cancer.
D000328:Adult; D000368:Aged; D004317:Doxorubicin / Q000009:adverse effects / Q000627:therapeutic use*; D004341:Drug Evaluation; D015251:Epirubicin; D006801:Humans; D007958:Leukocyte Count; D007970:Leukopenia / Q000139:chemically induced; D008175:Lung Neoplasms / Q000188:drug therapy*; D008875:Middle Aged
D015251:Epirubicin; D004317:Doxorubicin